 |
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
The mission of the Company is to become a global leader in stem cell gene therapy by using the Company's technologies to repair and/or compensate for mutations in defective genes. A unique aspect of the Company's non-viral process is that it is performed on a patient's stem cells outside the body or ex vivo. Stem cells are special cells in the body that are basic or building block cells which have the ability to continually create large numbers of more specialized cells. There are about 4,000 diseases that have been traced to gene disorders or mutations. ( VERY Large Market ) The Company is at the forefront of gene therapy research employing a delivery technique called glass needle mediated microinjection. Microinjection involves injecting cells with minute amounts of material using very small needles made of glass. In order to utilize this technique the Company had to develop new needles because commercially available needles were too large. The commercial needles were large enough that they would cause physical damage to the cell they were injecting. To remedy this problem the Company developed ultra-fine needles with a tip diameter of ~0.3 microns which is about 1/100 the diameter of a human hair. These smaller diameter needles made of glass are capable of delivering DNA without damaging the cell. In addition to the development of a smaller needle, the system developed by the Company requires that a cell be immobilized (that is, attached to a plastic dish or surface) in order to perform microinjection. The Company has made major advances in this area and has developed a novel proprietary method to immobilize cells without the loss of cell function. The development of this immobilization technology was critical to the success of the Company and comprises part of the first patent filing of the Company. The Company employs acceptable scientific methods of research, and their technology has been verified through test results and review both at the Company and at the University of Texas Medical Branch. This work has been presented in university lectures, at gene therapy conferences, and was recently published in Blood (Blood 95: 437-444, 2000), the Journal of the American Society of Hematology. In order to protect the Company's technology, the principles have filed for patents on the related technology. Look it over and you can see that this small co. is on it's way to being Very Big in the nitch ( Stem Cell ) and the Trillion Dollar market that it represents. IMO | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |